Tyrosine kinase inhibitor / senolytic

Plain-language summaryIntrigue 80 / 100

Dasatinib (Sprycel) is a multi-target kinase inhibitor approved in 2006 for chronic myeloid leukemia and Philadelphia-chromosome-positive ALL. The longevity world cares about it for a different reason: in 2015, Kirkland and Tchkonia at Mayo Clinic showed that dasatinib combined with quercetin (a natural flavonoid) selectively kills senescent cells, those zombie cells that accumulate with age and pump out inflammatory signals. The combination, dubbed D+Q, became the prototype senolytic regimen and is in human trials for diabetic kidney disease, Alzheimer disease, and idiopathic pulmonary fibrosis. The intermittent dosing (a few days per month) is meant to clear senescent cells without sustained kinase inhibitor exposure. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

60/100

Canonical senolytic tool compound with real clinical pipeline but evidence still maturing

Look, dasatinib is a case where the original compound and the interesting research are almost two different things. As a BCR-ABL/Src kinase inhibitor for CML, it’s a well-understood oncology tool that’s been on the market since 2006. That part of the story is mature. What we’re interested in here is the senolytic application, which is effectively a different compound in terms of what investigators are actually doing with it.

The Kirkland and Tchkonia group at Mayo Clinic is the origin point for the D+Q framing. The 2015 paper in Aging Cell showed that dasatinib preferentially kills senescent fat cell progenitors while leaving healthy cells largely intact, and quercetin covers the epithelial senescent cell population that dasatinib misses. The mechanism isn’t just “it’s cytotoxic”; it’s targeting the pro-survival networks senescent cells depend on: ephrin receptors, BCR-ABL-related kinase activity in mesenchymal lineages, PI3K/AKT signaling. Selective enough to be useful, broad enough to clear the target population. Thats a real biological lever, and it makes the D+Q framing more than a convenience stack.

Clinical translation is moving. There’s a 2019 pilot in idiopathic pulmonary fibrosis (Kirkland, published in EBioMedicine) showing improved physical function measures in a small N. Trials in diabetic kidney disease have shown some early eGFR-related signals. The Alzheimer’s indication is under active investigation across multiple sites. What we dont have yet is a clean phase 3 confirmation; the trials are phase 1/2, mostly single-site, and effect sizes in the early data are modest. The IPF result looks real but hasn’t been replicated at scale.

Where dasatinib earns its keep in a research library is bench utility. If you’re running a senolytic program, this is your reference compound for the mesenchymal compartment. You can’t do credible senolytic biology without it as a comparator. The combination with quercetin is the canonical positive control in the field. That’s indispensable tool value even before you factor in the clinical translation story.

What we like: the mechanism is genuinely interesting, the clinical pipeline is real, and this compound occupies a position no other small molecule currently fills in aging biology. What we don’t like: the evidence base for the senolytic indication is still early, the oncology-derived dosing (even the intermittent 3-days-per-month approach) carries a meaningful adverse effect profile that complicates healthy-aging research design, and the human signal needs considerably more work before anyone should treat this as a resolved story. Compelling for investigators in the senolytic space; not yet a priority for those working adjacent to it.

Novelty: 52
Mechanism promise: 65
In-category differentiation: 68
Evidence quality: 52
Translational signal: 55
Research bench value: 72

Rationale Dasatinib scores primarily on differentiation and bench utility as the reference mesenchymal senolytic in the D+Q combination; novelty is tempered by its 2006 approval and now-decade-old senolytic repurposing, and the clinical evidence base remains phase 1/2 with modest effect sizes and limited replication.

Tyrosine kinase inhibitor / senolytic

A multi-target tyrosine kinase inhibitor approved for chronic myeloid leukemia; repurposed in senolytic combination therapy with quercetin (D+Q).

Abstract

Dasatinib (BMS-354825; CAS 302962-49-8; molecular formula C22H26ClN7O2S; molecular weight 488.01) is a multi-target tyrosine kinase inhibitor developed at Bristol-Myers Squibb and approved by the FDA in 2006 under the trade name Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive ALL. The senolytic application emerged from work by Kirkland and Tchkonia at Mayo Clinic (2015 onward) demonstrating that the combination of dasatinib (targeting senescent cells of mesenchymal origin) and quercetin (targeting senescent cells of epithelial origin) selectively eliminates senescent cells while sparing healthy cells. The D+Q regimen has been advanced into multiple clinical trials in idiopathic pulmonary fibrosis, diabetic kidney disease, Alzheimer disease, and other age-related conditions, with intermittent dosing (e.g., 100 mg daily for 3 days monthly) hypothesized to clear accumulated senescent cells without continuous chemotherapy exposure. Plasma half-life is approximately 5 hours; metabolism is via CYP3A4. Used as the canonical senolytic small molecule with clinical translation.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-297Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Tyrosine kinase inhibitor / senolytic

Dasatinib

Abstract

Read the full monograph